CytomX Therapeutics, Inc. (NASDAQ:CTMX) Shares Purchased by Point72 Asset Management L.P.

Point72 Asset Management L.P. raised its stake in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) by 4,968.0% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 6,335,000 shares of the biotechnology company’s stock after purchasing an additional 6,210,000 shares during the period. Point72 Asset Management L.P. owned 9.74% of CytomX Therapeutics worth $48,970,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. First Trust Advisors LP acquired a new stake in shares of CytomX Therapeutics in the first quarter worth $263,000. Rhumbline Advisers increased its position in shares of CytomX Therapeutics by 5.9% in the fourth quarter. Rhumbline Advisers now owns 59,141 shares of the biotechnology company’s stock worth $387,000 after acquiring an additional 3,310 shares in the last quarter. Citigroup Inc. increased its position in shares of CytomX Therapeutics by 139.5% in the fourth quarter. Citigroup Inc. now owns 11,447 shares of the biotechnology company’s stock worth $75,000 after acquiring an additional 6,667 shares in the last quarter. Barclays PLC increased its position in shares of CytomX Therapeutics by 204.7% in the fourth quarter. Barclays PLC now owns 90,014 shares of the biotechnology company’s stock worth $589,000 after acquiring an additional 60,474 shares in the last quarter. Finally, Lazard Asset Management LLC acquired a new stake in shares of CytomX Therapeutics in the fourth quarter worth $54,000. 83.97% of the stock is owned by hedge funds and other institutional investors.

Several research firms have recently issued reports on CTMX. Barclays lowered shares of CytomX Therapeutics from an “equal weight” rating to an “underweight” rating and dropped their price objective for the stock from $9.00 to $7.00 in a research report on Friday, May 28th. Zacks Investment Research raised shares of CytomX Therapeutics from a “hold” rating to a “buy” rating and set a $6.50 price target for the company in a report on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of CytomX Therapeutics in a report on Tuesday, July 6th. Finally, JPMorgan Chase & Co. assumed coverage on shares of CytomX Therapeutics in a report on Monday, March 29th. They set an “overweight” rating and a $14.00 price target for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $9.60.

In other news, CEO Sean A. Mccarthy sold 100,000 shares of the firm’s stock in a transaction dated Wednesday, June 16th. The shares were sold at an average price of $7.04, for a total value of $704,000.00. Following the transaction, the chief executive officer now directly owns 7,849 shares in the company, valued at approximately $55,256.96. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 5.80% of the company’s stock.

NASDAQ CTMX opened at $5.89 on Thursday. CytomX Therapeutics, Inc. has a 12 month low of $5.63 and a 12 month high of $10.05. The company’s fifty day moving average is $6.94.

CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings data on Thursday, May 6th. The biotechnology company reported ($0.26) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.29) by $0.03. CytomX Therapeutics had a negative net margin of 90.87% and a negative return on equity of 80.13%. The firm had revenue of $15.97 million for the quarter, compared to the consensus estimate of $20.32 million. On average, equities research analysts predict that CytomX Therapeutics, Inc. will post -1.09 earnings per share for the current fiscal year.

CytomX Therapeutics Profile

CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors.

Recommended Story: Price-Sales Ratio

Want to see what other hedge funds are holding CTMX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CytomX Therapeutics, Inc. (NASDAQ:CTMX).

Institutional Ownership by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.